课题基金 / 基金详情

项目摘要

项目成果

Katherine L. Knight的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The host and its commensal microbiota generally maintain a peaceful coexistence; however, a few bacteria disrupt immune homeostasis and cause disease. For example, attaching and effacing (A/E) enteropathogenic and enterohemorrhagic E. coli (EPEC and EHEC) cause diarrheal diseases that affect more than 2 billion people and kill 1.5 million children annually. Commensal bacteria can protect the host from disease caused by enteric pathogens; however, the mechanisms by which this occurs are poorly understood. We recently found that a single oral dose of commensal Bacillus subtilis or Bacillus formis spores can protect mice from disease caused by the A/E pathogen, Citrobacter rodentium. In contrast, a closely related commensal Bacillus licheniformis, and two B. subtilis mutants, hag and espH, did not protect the host. Because the single dose of protective Bacillus spp. is given 24 hr prior to pathogenic C. rodentium, protection is not likely due to initiation of an adaptive immune response, but is more likely due to an innate anti-inflammatory immune response. Alternatively, Bacillus spp. could protect from disease by directly interfering with localization of C. rodentium to the intestinal epithelium. In Aim 1 we will use in vivo bioluminescence imaging (IBIS) to determine if protective Bacillus spp. alter the colonization site of pathogenic C. rodentium. One of the non-protective B. subtilis mutants is deficient in flagellin, a ligand for TLR5, and another is deficient in exopolysaccharide, presumed ligand for TLR2, and in Aim 2 we will use TLR agonists and TLR knockout mice to determine if protection is mediated through TLR. Similarly, we will use Nod-like receptor (NLR) agonists and knockout mice to determine if protection is mediated through NLR. In Aim 3, we will test the possibility that B. subtilis mediates protection through T regulatory cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a mucosal vaccine to prevent Clostridium difficile infection using papilloma pseudovirus as a vector.
  • 批准号:
    10213890
  • 项目类别:
  • 资助金额:
    $50.23万
  • 财政年份:
    2020
  • 负责人:
    Katherine L. Knight
  • 依托单位:
Prevention of GVHD by a probiotic exopolysaccharide.
  • 批准号:
    10081555
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2020
  • 负责人:
    Katherine L. Knight
  • 依托单位:
Microbe-driven Development of GALT
  • 批准号:
    10399453
  • 项目类别:
  • 资助金额:
    $46.18万
  • 财政年份:
    2018
  • 负责人:
    Katherine L. Knight
  • 依托单位:
Microbe-driven Development of GALT
  • 批准号:
    9924442
  • 项目类别:
  • 资助金额:
    $45.98万
  • 财政年份:
    2018
  • 负责人:
    Katherine L. Knight
  • 依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    乔安娜
  • 依托单位: